Human innate immunity employs cellular and humoral mechanisms to facilitate rapid 27 killing of invading bacteria. The direct killing of bacteria by human serum is mainly 28 attributed to the activity of the complement system that forms pores in Gram-negative 29 bacteria. Although Gram-positive bacteria are considered resistant to serum killing, 30 we here uncover that normal human serum effectively kills Enterococcus faecium. 31 Comparison of a well-characterized collection of commensal and clinical E. faecium 32 isolates revealed that human serum specifically kills commensal E. faecium strains 33 isolated from normal gut microbiota, but not clinical isolates. Inhibitor studies show 34 that the human group IIA secreted phospholipase A2 (hGIIA), but not complement, is 35 responsible for killing of commensal E. faecium strains in human normal serum. This 36 is remarkable since hGIIA concentrations in 'non-inflamed' serum were considered 37 too low to be bactericidal against Gram-positive bacteria. Mechanistic studies showed 38 that serum hGIIA specifically causes permeabilization of commensal E. faecium 39 membranes. Altogether, we find that a normal serum concentration of hGIIA 40 effectively kills commensal E. faecium and that hGIIA resistance of clinical E. 41 faecium could have contributed to the ability of these strains to become opportunistic 42 pathogens in hospitalized patients. 43 44 Importance 45 Human normal serum contains antimicrobial components that effective kill invading 46 Gram-negative bacteria. Although Gram-positive bacteria are generally considered 47 resistant to serum killing, here we show that normal human effectively kills the Gram-48 positive Enterococcus faecium strains that live as commensals in the gut of humans. 49 In contrast, clinical E. faecium strains that are responsible for opportunistic infections 50 3 in debilitated patients are resistant against human serum. The key factor in serum 51 responsible for killing is group IIA secreted phospholipase A2 (hGIIA) that 52 effectively destabilizes commensal E. faecium membranes. We believe that hGIIA 53 resistance by clinical E. faecium could have contributed to the ability of these strains 54 to cause opportunistic infections in hospitalized patients. Altogether, understanding 55 mechanisms of immune defense and bacterial resistance could aid in further 56 development of novel anti-infective strategies against medically important multidrug 57 resistant Gram-positive pathogens. 58 59
Abstract 26 Human innate immunity employs cellular and humoral mechanisms to facilitate rapid 27 killing of invading bacteria. The direct killing of bacteria by human serum is mainly 28 attributed to the activity of the complement system that forms pores in Gram-negative 29 bacteria. Although Gram-positive bacteria are considered resistant to serum killing, 30 we here uncover that normal human serum effectively kills Enterococcus faecium. 31 Comparison of a well-characterized collection of commensal and clinical E. faecium 32 isolates revealed that human serum specifically kills commensal E. faecium strains 33 isolated from normal gut microbiota, but not clinical isolates. Inhibitor studies show 34 that the human group IIA secreted phospholipase A2 (hGIIA), but not complement, is 35 responsible for killing of commensal E. faecium strains in human normal serum. This 36 is remarkable since hGIIA concentrations in 'non-inflamed' serum were considered 37 too low to be bactericidal against Gram-positive bacteria. Mechanistic studies showed 38 that serum hGIIA specifically causes permeabilization of commensal E. faecium 39 membranes. Altogether, we find that a normal serum concentration of hGIIA 40 effectively kills commensal E. faecium and that hGIIA resistance of clinical E. 41 faecium could have contributed to the ability of these strains to become opportunistic 42 pathogens in hospitalized patients. 43 44 Importance 45 Human normal serum contains antimicrobial components that effective kill invading 46 Gram-negative bacteria. Although Gram-positive bacteria are generally considered 47 resistant to serum killing, here we show that normal human effectively kills the positive Enterococcus faecium strains that live as commensals in the gut of humans. 49 In contrast, clinical E. faecium strains that are responsible for opportunistic infections 50 in debilitated patients are resistant against human serum. The key factor in serum 51 responsible for killing is group IIA secreted phospholipase A2 (hGIIA) that 52 effectively destabilizes commensal E. faecium membranes. We believe that hGIIA 53 resistance by clinical E. faecium could have contributed to the ability of these strains 54 to cause opportunistic infections in hospitalized patients. Altogether, understanding 55 mechanisms of immune defense and bacterial resistance could aid in further Introduction 60 The human immune system is essential to protect us against invading bacterial 61 infections. The first line of immune defense is comprised of cellular and humoral 62 factors that together fight infections in the first minutes to hours of an infection 63 against bacteria. Phagocytic cells, such as neutrophils are able to engulf invading 64 bacteria by bacterial recognition, which is enhanced by bacterial labeling with serum 65 factors as antibodies and complement activation products (1). However, human serum 66 also harbors various antimicrobial proteins and peptides that can directly lyse bacteria 67 without the help of immune cells (2). This serum bactericidal activity is mainly 68 effective against Gram-negative bacteria that are sensitive for the pore-forming 69 Membrane Attack Complex (MAC) of the human complement system (3). For long it 70 has been known that Gram-positive bacteria are resistant to this 'serum bactericidal 71 activity'. It is generally assumed that all Gram-positive bacteria (both pathogenic and 72 non-pathogenic) protect themselves against complement-induced pore formation via a 73 thick layer of peptidoglycan that surrounds the bacterial membrane (4). We here 74 found that normal human serum selectively kills commensal E. faecium strains, 75 whereas disease-associated E. faecium strains remain viable. 76 Enterococcus faecium is a common inhabitant of the gut of mammals, birds and 77 insects (5, 6 
Results

97
Human serum kills commensal but not clinical Enterococcus faecium strains. 98 While human serum effectively kills Gram-negative bacteria (20), it is generally 99 accepted that serum does not kill pathogenic and non-pathogenic Gram-positives (21). 100 Serendipitously however, we discovered that a commensal strain of E. faecium 101 (E1007, isolated from feces of a healthy individual) was effectively killed by human 102 serum. We incubated 10 5 exponential phase E. faecium E1007 with normal human 103 serum (pooled from 20 healthy volunteers) and quantified bacterial survival via 104 colony enumeration on agar plates ( Fig 1A) . Within 30 minutes, 10% human serum 105 could completely kill 10 5 E1007 bacteria. In contrast, a clinical E. faecium strain 106 (E1162, isolated from blood of a hospitalized patient) was fully resistant to serum 107 killing in a similar assay. Based on these results, we extended these analyses to a 108 broader panel of genomically well-characterized clinical and commensal E. faecium 109 isolates. We selected clinical E. faecium strains isolated from hospitalized patients 110 and compared their serum susceptibility to a selection of commensal E. faecium 111 isolated from healthy individuals or animals. Exposure of all 19 strains (described in 112 Table 1 ) to 25% human serum revealed that human serum specifically kills 113 commensal strains by 70% reduction on average, but not clinical E. faecium strains, 114 which survive for 98% ( Fig 1B) . 118 To investigate how human serum kills commensal E. faecium strains, we first used 119 several approaches to inactivate the complement system. Bactericidal activity of the 120 complement system is mediated by the Membrane Attack Complex (MAC), a ring-121 structured pores consisting of proteins C5b, C6, C7, C8 and multiple copies of C9 122 (C5b-9). Formation of pores in bacterial membranes occurs rapidly following an 123 enzymatic chain reaction on the cell surface. Initial experiments seemed to suggest 124 that complement indeed played a role in killing of E. faecium. For instance, we found 125 that E. faecium killing could be blocked by exposing the serum to 56ºC (heat-126 inactivated (HI) serum), a method commonly used to inactivate certain heat-labile 127 complement components (22) (Fig 2A-B) . Furthermore, addition of the chelating 128 agent (Ethylenediaminetetraacetic acid -EDTA), known to block the complement 129 reaction (23), also interfered with serum killing (Fig 2A, B) . However, when we used 130 more specific inhibitors to block the complement reaction, we found that these 131 inhibitors did not affect serum-mediated killing of E. faecium (Fig 2A) . For instance, 132 application of C3 inhibitor CP40 (24) and C5 inhibitor OmCI (25) did not block 133 bactericidal activity (Fig 2A) , although both inhibitors effectively blocked MAC 134 deposition on the bacterial surface ( Fig 2B) . Resistance of the clinical E. faecium 135 strain E1162 was not affected by any of the serum treatments (S1 Fig serum. We observed that the inhibitor blocks the killing activity in a dose dependent 153 manner ( Fig 3A) and at different concentrations of human serum ( Fig 3B) . Moreover, faecium strains ( Fig 4B) . Confocal microscopy confirmed membrane damage of the 174 commensal E. faecium E1007 strain but not clinical E1162 strain by human serum 175 ( Fig 4C) with different DNA dyes (syto9 and propidium iodide). Furthermore, we 176 found that the serum-induced membrane permeabilization of the E1007 strain was 177 mediated by hGIIA, since EDTA and hGIIA inhibition blocked the observed sytox 178 influx ( Fig 4D) . Finally, we found that all tested commensal, but not clinical E. 179 faecium isolates are sensitive to membrane permeabilization via hGIIA in human 180 serum ( Fig 4E) . 181 Altogether we conclude that hGIIA is the principal component of human serum, Normal human serum (HS) was generated at the department of medical microbiology, 253 UMC Utrecht. As previously described (21) 1 Clade structure was based on the classification described by Paganelli et al. (46) 
